Wall Street analysts expect TransMedics (TMDX) to post quarterly loss of $0.05 per share in its upcoming report, which indicates a year-over-year increase of 37.5%. Revenues are expected to be $83.32 million, up 100.5% from the year-ago quarter.The current level reflects an upward revision of 32.2% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a compa ...

The most recent trading session ended with TransMedics (TMDX) standing at $88.88, reflecting a -1.9% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.11%, and the technology-dominated Nasdaq saw an increase of 0.1%.Prior to today's trading, shares of the medical technology company had gained 21.63% over the past month. This has outpaced the Medical sector's loss of 4.52% and the S&P 500's loss of ...

TransMedics (TMDX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 30. O ...

TransMedics (TMDX) closed the most recent trading day at $84.74, moving +0.69% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 0.87% for the day. Elsewhere, the Dow saw an upswing of 0.67%, while the tech-heavy Nasdaq appreciated by 1.11%.Shares of the medical technology company witnessed a gain of 18.77% over the previous month, beating the performance of the Medical sector with its loss of 6.67% and the S&P 500's loss of 3.97%.Investors will be eagerly wa ...

ANDOVER, Mass., April 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2024 after market close on Tuesday, April 30, 2024. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT. Investors interested in listen ...

In the latest market close, TransMedics (TMDX) reached $91.82, with no movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss of 1.2%. On the other hand, the Dow registered a loss of 0.65%, and the technology-centric Nasdaq decreased by 1.79%.Prior to today's trading, shares of the medical technology company had gained 20.91% over the past month. This has outpaced the Medical sector's loss of 6.57% and the S&P 500's loss of 0.85% in that time.Market participants ...

uchar/E+ via Getty Images Increasingly unhealthy lifestyles are leading to a higher incidence of organ failure worldwide, and while organ transplantation is generally the preferred treatment for organ failure due to better outcomes and quality of life, organ supply is currently heavily constrained for a variety of reasons, leading to a waiting list that as of 2023, numbers over 100,000 patients in the U.S. alone. American medtech company TransMedics’s (NASDAQ:TMDX) disruptive FDA-approved medical device ...

sturti TransMedics Group, Inc. (NASDAQ:TMDX), a company you probably never heard of, is transforming the organ transplant landscape. This is a rare opportunity to invest in a company that's going to save thousands of lives (and already has), at a very early stage, but with already proven capabilities and FDA approvals. Let's dive in. Introduction To TransMedics TransMedics Group was founded in 1998 by Dr. Waleed H. Hassanein. It is a medical technology company focused on transforming organ transplant therap ...

ANDOVER, Mass., Feb. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference in Boston on Monday, March 4, 2024, at 9:50 a.m. EST and to presen ...

TransMedics Group, Inc. (NASDAQ:TMDX) Q4 2023 Earnings Conference Call February 26, 2024 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group, IR Waleed Hassanein - President and CEO Stephen Gordon - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Josh Jennings - TD Cowen Bill Plovanic - Canaccord Ryan Daniels - William Blair Suraj Kalia - Oppenheimer & Company Operator Good afternoon. And welcome to the TransMedics Fourth Quarter and Full Year 2023 Earnings Conference ...